Evommune Doses First Patient in Phase 2b Migraine Trial for EVO756, Top-Line Data Expected 2027
EVMN is trading near its 52-week low of $10.47 (4.1% above the low) on light trading volume (0.4× avg).
Summary
Evommune initiates a Phase 2b trial of EVO756 in migraine prophylaxis, a new indication after the drug's recent failure in CSU. Top-line data is expected in 2027.
Key Events · Product Development and Regulatory · EVMN
-
Phase 2b Migraine Trial Initiated
First patient dosed in a global, randomized, double-blind, placebo-controlled Phase 2b trial of EVO756 for migraine prophylaxis. Approximately 330 patients will be randomized across two active dose arms and placebo for 12 weeks.
-
Strategic Pivot After CSU Failure
This trial comes one month after EVO756 failed its Phase 2b trial in chronic spontaneous urticaria (CSU), leading the company to halt that program. Migraine represents a new indication with a differentiated mechanism targeting MRGPRX2.
-
Top-Line Data Expected in 2027
The company expects to report top-line data from the migraine trial in 2027, leaving a significant gap before the next major catalyst.
-
Cash Runway Through 2028
Evommune reported $307.0 million in cash as of Q1 2026, following a $117.2 million private placement at $27.88 per share, providing runway through 2028 to fund this trial.
Analysis · EVMN · Life Sciences
Evommune has dosed the first patient in a Phase 2b trial of EVO756 for migraine prophylaxis, marking a strategic pivot after the drug failed a Phase 2b trial in chronic spontaneous urticaria (CSU) just one month ago. The trial targets a new indication with a differentiated mechanism — MRGPRX2 inhibition — and could open a large market opportunity if successful. However, the stock is trading near its 52-week low following the CSU failure, and the trial's top-line data is not expected until 2027, leaving a long wait for investors. The company's cash runway through 2028 provides some cushion, but the near-term catalyst is limited to trial enrollment updates.
At the time of this filing, EVMN was trading at $10.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $398M. The 52-week trading range was $10.47 to $33.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.